drugset / Trial / NCT01906632

Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy

NCT01906632

Completed 50 enrolled Capital Medical University
NaSingle-groupOpen-labelTreatment

Summary

To investigate gene expression profile and immunological associated analysis relating to immunotherapy response of patients with malignant tumor after DC-CIK immunotherapy.

Timeline

Start
2013-05
Primary completion
2022-12-30
Completion
2023-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject DC-CIK Cell therapy

Indications